Mitochondrial toxicity is a limiting factor in the use of some nucleoside reverse transcriptase inhibitors of HIV. To further understand the impact of structural features on the incorporation and exonuclease removal of nucleoside monophosphate (MP) analogues by human mitochondrial DNA polymerase (pol γ), transient kinetic studies were done with analogues of 2′-deoxyguanosine triphosphate. The kinetic parameters for the incorporation and removal of carbovir (CBV)-MP, dioxolane guanosine (DXG)-MP and 2′,3′-dideoxy-2′,3′-didehydroguanosine (d4G)-MP were studied with pol γ holoenzyme. The importance of the ribose oxygen in incorporation by pol γ was illustrated by an approximate 3,000-fold decrease in the incorporation efficiency of an analogue lacking the ribose oxygen (CBV-TP) relative to those containing a ribose oxygen (DXG-TP and d4G-TP). As a result, a comparison with previous data for the incorporation by HIV reverse transcriptase showed CBV-TP to be approximately 800–8,000-fold more selective for its antiviral target over pol γ relative to the other guanosine analogues. However, DXG-TP and d4G-TP were found to be much more selective than previously reported values for mitochondrial toxic nucleoside analogues. Structural modelling based on sequence homology with other polymerase A family members suggests that an interaction between the ribose oxygen and arginine 853 in pol γ may play a critical role in causing this differential incorporation. Exonuclease removal of a chain-terminating CBV-MP was also found to be more efficient by pol γ. These results help to further elucidate the structure activity relationships for pol γ and should aid in the design of more selective antiviral agents.
AstatkeMNgKGrindleyND & JoyceCM (1998) A single side chain prevents Escherichia coli DNA polymerase I (Klenow fragment) from incorporating ribonucleotides. Proceedings of the National Academy of Sciences of the United States of America95: 3402–3407.
2.
BackDJBurgerDMFlexnerCW & GerberJG (2005) The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: Implications for once-daily dosing. Journal of Acquired Immune Deficiency Syndromes39Suppl 1: S1–S23.
3.
BirkusGHitchcockMJ & CihlarT (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy46: 716–723.
4.
CarrodeguasJAKobayashiRLimSECopelandWC & BogenhagenDF (1999) The accessory subunit of Xenopus laevis mitochondrial DNA polymerase gamma increases processivity of the catalytic subunit of human DNA polymerase gamma and is related to class II aminoacyl-tRNA synthetases. Molecular and Cellular Biology19: 4039–4046.
5.
DalugeSMGoodSSFalettoMBMillerWHSt ClairMHBooneLRTisdaleMParryNRReardonJEDornsifeREAverettDR & KrenitskyTA (1997) 1592U89, a novel carbocyclic nucleoside analogue with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents and Chemotherapy41: 1082–1093.
6.
DelarueMPochOTordoNMorasD & ArgosP (1990) An attempt to unify the structure of polymerases. Protein Engineering3: 461–467.
7.
DoublieS & EllenbergerT (1998) The mechanism of action of T7 DNA polymerase. Current Opinion in Structural Biology8: 704–712.
8.
FalettoMBMillerWHGarveyEPSt ClairMHDalugeSM & GoodSS (1997) Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrobial Agents and Chemotherapy41: 1099–1107.
9.
FengJYJohnsonAAJohnsonKA & AndersonKS (2001) Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. Journal of Biological Chemistry276: 23832–23837.
10.
FengJYMurakamiEZorcaSMJohnsonAAJohnsonKASchinaziRFFurmanPA & AndersonKS (2004) Relationship between antiviral activity and host toxicity: Comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrobial Agents and Chemotherapy48: 1300–1306.
11.
FurmanPAJeffreyJKieferLLFengJYAndersonKSBorroto-EsodaKHillECopelandWCChuCKSommadossiJPLibermanISchinaziRF & PainterGR (2001) Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrobial Agents and Chemotherapy45: 158–165.
12.
GravesSWJohnsonAA & JohnsonKA (1998) Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase. Biochemistry37: 6050–6058.
13.
GraziewiczMALongleyMJBienstockRJZevianiM & CopelandWC (2004) Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nature Structural & Molecular Biology11: 770–776.
14.
GripshoverBMRibaudoHSantanaJGerberJGCampbellTBHoggEJarockiBHammerSM & KuritzkesDR (2006) Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivirial Therapy11: 619–623.
15.
JeffreyJLFengJYQiCCAndersonKS & FurmanPA (2003) Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. Journal of Biological Chemistry278: 18971–18979.
16.
JohnsonAARayASHanesJSuoZColacinoJMAndersonKS & JohnsonKA (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. Journal of Biological Chemistry276: 40847–40857.
17.
JohnsonAATsaiYGravesSW & JohnsonKA (2000) Human mitochondrial DNA polymerase holoenzyme: Reconstitution and characterization. Biochemistry39: 1702–1708.
18.
JoyceCM & SteitzTA (1994) Function and structure relationships in DNA polymerases. Annual Review of Biochemistry63: 777–822.
19.
KatiWMJohnsonKAJervaLF & AndersonKS (1992) Mechanism and fidelity of HIV reverse transcriptase. Journal of Biological Chemistry267: 25988–25997.
20.
LarderBA (1995) Viral resistance and the selection of antiretroviral combinations. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology10Suppl 1: S28–S33.
21.
LeeHHanesJ & JohnsonKA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry42: 14711–14719.
22.
LiYKorolevS & WaksmanG (1998) Crystal structures of open and closed forms of binary and ternary complexes of the large fragment of Thermus aquaticus DNA polymerase I: Structural basis for nucleotide incorporation. Embo Journal17: 7514–7525.
23.
LimSE & CopelandWC (2001) Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. Journal of Biological Chemistry276: 23616–23623.
24.
LimSEPonamarevMVLongleyMJ & CopelandWC (2003) Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. Journal of Molecular Biology329: 45–57.
25.
MartinLTFarajASchinaziRFGosselinGMatheCImbachJL & SommadossiJP (1997) Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells. Biochemical Pharmacology53: 75–87.
26.
MurakamiERayASSchinaziRF & AndersonKS (2004) Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: Comparison of D- and L-D4FC-TP. Antiviral Research62: 57–64.
27.
NaegerLK & MillerMD (2001) Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: Is it all figured out?Current Opinion in Investigational Drugs2: 335–339.
28.
NolanD & MallalS (2004) Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms. Antiviral Therapy9: 849–863.
29.
ParkerWB & ChengY-C (1994) Mitochondrial toxicity of antiviral nucleoside analogs. Journal of NIH Research6: 57–61.
30.
PoleskyAHDahlbergMEBenkovicSJGrindleyND & JoyceCM (1992) Side chains involved in catalysis of the polymerase reaction of DNA polymerase I from Escherichia coli. Journal of Biological Chemistry267: 8417–8428.
31.
PoleskyAHSteitzTAGrindleyND & JoyceCM (1990) Identification of residues critical for the polymerase activity of the Klenow fragment of DNA polymerase I from Escherichia coli. Journal of Biological Chemistry265: 14579–14591.
32.
PonamarevMVLongleyMJNguyenDKunkelTA & CopelandWC (2002) Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis. Journal of Biological Chemistry277: 15225–15228.
33.
RayAS (2005) Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Review7: 113–125.
34.
RayASHernandez-SantiagoBIMathewJSMurakamiEBozemanCXieMYDutschmanGEGullenEYangZHurwitzSChengYCChuCKMcClureHSchinaziRF & AndersonKS (2005) Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2′,3′-didehydro-2′,3′-dideoxyguanosine. Antimicrobial Agents and Chemotherapy49: 1994–2001.
35.
RayASYangZChuCK & AndersonKS (2002a) Novel use of a guanosine prodrug approach to convert 2′,3′-didehydro-2′,3′-dideoxyguanosine into a viable antiviral agent. Antimicrobial Agents and Chemotherapy46: 887–891.
36.
RayASYangZShiJHobbsASchinaziRFChuCK & AndersonKS (2002b) Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry41: 5150–5162.
37.
SarafianosSGDasKClarkADJr.DingJBoyerPLHughesSH & ArnoldE (1999) Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proceedings of the National Academy of Sciences of the United States of America96: 10027–10032.
38.
SchinaziRFLloydRMJr.NguyenMHCannonDLMcMillanAIlksoyNChuCKLiottaDCBazmiHZ & MellorsJW (1993) Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy37: 875–881.
39.
ThompsonMAKesslerHAEronJJJr.JacobsonJMAddaNShenGZongJHarrisJMoxhamC & RousseauFS (2005) Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS19: 1607–1615.
40.
TisdaleMAlnadafT & CousensD (1997) Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents and Chemotherapy41: 1094–1098.
41.
TisdaleMKempSDParryNR & LarderBA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America90: 5653–5656.
42.
WangYFarrCL & KaguniLS (1997) Accessory subunit of mitochondrial DNA polymerase from Drosophila embryos. Cloning, molecular analysis, and association in the native enzyme. Journal of Biological Chemistry272: 13640–13646.
43.
WhiteAJ (2001) Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections77: 158–173.
44.
WhiteELParkerWBMacyLJShaddixSCMcCalebGSecristJA3rdVinceR & ShannonWM (1989) Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochemical and Biophysical Research Communications161: 393–398.
